Iodide I-131 is a radioisotopic agent used for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay.
- Mechanism
- Curator reviewed
Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.
- Primary indication
- Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine.Curator reviewed · 5 structured indications
- Formula / weight
- I · 130.9067 g/mol (avg)
- First approval
- United States, 1957
- Also known as
- 131 I · 131-I · 131I · Iodide I-131 ion · Iodide-131
- Brand names
Resolves to
XMBWDFGMSWQBCA-RNFDNDRNSA-MSMILES[131I-]What you can answer from here — as of September 13, 2026
Which drugs share a target with Iodide I-131, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account